CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization
American Journal of Translational Research · 2025 · 17 (2) · 1076-1086
DOI: 10.62347/btyn8678 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2025. Verfasst von Jie Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Wujin Hospital Affiliated with Jiangsu University Changzhou 213003, Jiangsu, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
This study seeks to identify new drug targets for Primary Sclerosing Cholangitis (PSC), a condition currently lacking effective treatment, to improve survival without transplantation.
Methods
We obtained summary statistics for 2,888 druggable genes and PSC from the eQTLGen Consortium and the FinnGen consortium, respectively.Through two-sample Mendelian randomization using the Inverse Variance Weighted (IVW) method, we identified genes associated with PSC at a False Discovery Rate (FDR) < 0.05.Further validation came from colocalization and Summary-data-based Mendelian Randomization (SMR) analyses, confirming the reliability of our results.
Results
Five druggable genes were causally associated with PSC at FDR < 0.05.Subsequent colocalization and SMR analyses further confirmed that higher levels of CDC42 in plasma were associated with an increased risk of PSC (IVW method: Odds Ratio 1.319, 95% Confidence Interval 1.182-1.471,P = 6.85E-07,FDR = 0.002).
Conclusions
Our research pioneered the identification of CDC42 as a target for slowing PSC progression.Our research not only uncovers a possible drug target but also provides direction for the development of therapeutics for PSC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, The Wujin Hospital Affiliated with Jiangsu University Changzhou 213003, Jiangsu, China.
- Department of General Surgery, The Wujin Clinical College of Xuzhou Medical University Changzhou 213003, Jiangsu, China.
- Department of General Surgery, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.
Zitieren
APA
Zhou, J., Xu, Y., Wang, H., Chen, C., & Wang, K. (2025). CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization. American Journal of Translational Research, 17(2), 1076-1086. https://doi.org/10.62347/btyn8678
Vancouver
Zhou J, Xu Y, Wang H, Chen C, Wang K. CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization. American Journal of Translational Research. 2025;17(2):1076-1086. doi:10.62347/btyn8678
BibTeX
@article{Zhou2025,
author = {Zhou, Jie and Xu, Yixin and Wang, Haitao and Chen, Chao and Wang, Kun},
title = {CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization},
journal = {American Journal of Translational Research},
year = {2025},
volume = {17},
number = {2},
pages = {1076--1086},
doi = {10.62347/btyn8678}
}
EUVIMED